Melakukan tes titer antibodi atau suntikan booster MMR (campak–gondongan–rubela) sebagai orang dewasa saat campak kembali merebak pada 2025, atau melewatkannya?
Jika Anda bertindak
Tes titer atau dosis booster MMR dewasa
0,001%
Jika Anda tidak bertindak
Melewatkan titer/booster, mengandalkan imunitas masa kecil
6,0%
Persentase orang yang kemudian menyesali setiap pilihan. Diagram batang dan catatan lengkap ditampilkan di bawah.
Kesehatan
Terakhir ditinjau 2026-06-13
Kualitas bukti 4.1/5
Skor tinjauan delapan dimensi terhadap
rubrik kualitas
. Setiap dimensi dinilai 1–5.
D1 Verifikasi sumber
5/5
D2 Otoritas & independensi sumber
5/5
D3 Akurasi tingkat penyesalan
3/5
D4 Keterbandingan sumber
3/5
D5 Pola Gilovich
4/5
D6 Kualitas prosa
4/5
D7 Kelengkapan peringatan
4/5
D8 Kualitas sampel
5/5
Rata-rata4.1/5
Data proksi — tidak ada survei penyesalan langsung untuk keputusan ini. Tingkat diturunkan dari skor kepuasan dan data hambatan akses daripada pertanyaan yang langsung menanyakan tentang penyesalan. Lihat peringatan di bawah.
Penyesalan atas tindakan
Tes titer atau dosis booster MMR dewasa
0,001%
<0.001% — proxy: a serious adverse event (anaphylaxis) is the only material downside; redundancy in an already-immune adult is not a regret-worthy outcome
US adults who seek an MMR titer or a precautionary MMR dose (1963-67 killed-vaccine cohort, healthcare personnel, immunocompromised contacts) during the 2025 resurgence
Per dose administered
Penyesalan atas kelambanan
Melewatkan titer/booster, mengandalkan imunitas masa kecil
6,0%
~6% — proxy: share of a US healthcare-worker serosurvey lacking a measles immunity marker (seronegative + equivocal); an upper bound on who carries an immunity gap, not a measured regret rate
US adults in the named higher-risk cohorts (1963-67 killed-vaccine recipients, healthcare personnel, immunocompromised) who skip serologic check or revaccination during the 2025 resurgence
Cross-sectional immunity gap during the 2025 resurgence
% menyesal dengan pilihan ini
Tes titer atau dosis booster MMR dewasaMelewatkan titer/booster, mengandalkan imunitas masa kecil
0,001%6,0%
inaction dominates — Tidak bertindak mendominasi — sebagian besar menyesali karena tidak bertindak.
Keputusan terkait
Keputusan yang serupa secara semantik — area yang sama, kompromi yang berbeda.
Melewatkan atau menolak vaksin dewasa yang direkomendasikan (tanpa suntik flu tahunan, tanpa booster COVID, tanpa vaksin herpes zoster di usia 50+, tanpa catch-up HPV)Mengikuti jadwal vaksin dewasa yang direkomendasikan (flu tahunan, booster COVID-19, herpes zoster di usia 50+, catch-up HPV hingga 45)
Melewatkan atau menolak vaksin perjalanan yang direkomendasikan (tanpa hep A atau tifoid sebelum Asia Selatan/Tenggara, tanpa demam kuning sebelum Afrika atau Amerika Selatan endemis, tanpa ensefalitis Jepang untuk Asia pedesaan)Mendapatkan vaksin perjalanan yang direkomendasikan sesuai panduan CDC/WHO berdasarkan tujuan sebelum berangkat (hep A dan tifoid untuk tujuan non-Barat, demam kuning untuk zona endemis, JE untuk tinggal ≥1 bulan di Asia pedesaan)
Melewatkan, menunda, atau menolak secara selektif vaksin anak (tanpa MMR, tanpa DTaP, jadwal alternatif, atau penolakan penuh)Mengikuti jadwal imunisasi anak yang direkomendasikan CDC/AAP (MMR, DTaP, polio, Hib, hepatitis B, varisela, dll., sesuai jadwal)
Mengonsumsi regimen kemoprofilaksis antimalaria yang direkomendasikan CDC/WHO (atovaquone-proguanil/Malarone, doxycycline, atau mefloquine) sebelum, selama, dan setelah perjalanan ke destinasi endemik malariaMelewatkan kemoprofilaksis antimalaria dan hanya mengandalkan pencegahan gigitan nyamuk (DEET, pakaian dengan permetrin, jaring, kelambu tempat tidur) untuk perjalanan ke destinasi endemik malaria
Menunda atau membatalkan perjalanan terjadwal karena sakit akut, operasi baru, kehamilan dengan komplikasi, imunokompromi, atau wabah aktif di destinasiTetap melakukan perjalanan sesuai rencana meskipun mengalami sakit akut, operasi baru, komplikasi kehamilan, imunokompromi saat ada wabah di destinasi, atau peringatan kedirgantaraan-medis lainnya
No survey asks adults whether they regret getting, or skipping, a measles booster during the 2025 resurgence. The few documented post-outbreak interviews run the other way: the parents of the Texas child who died in 2025 told reporters they stood by their decision not to vaccinate. So this pair is a proxy. The action side is anchored on the probability of a serious adverse event from the shot itself, and the inaction side on the share of the relevant cohort that carries no measurable measles immunity. Neither number is a regret rate; both are stand-ins, and the gap between them is wide.
The action downside is small and well-characterized. Anaphylaxis after an MMR-containing vaccine was reported to VAERS at 0.6 per million doses over 1990 to 2016, and the CDC’s Vaccine Information Statement describes a serious reaction as a “very remote chance.” The common outcomes — a sore arm, a brief fever, a mild rash — are not the kind of thing people later regret. The subtler point is that for the large majority of adults who turn out to have been immune already, the booster was redundant rather than harmful, and a redundant-but-protective dose tends to read as reassurance, not as a mistake. That is why the action proxy sits near the floor: the only genuinely regret-worthy action outcome is the rare serious event, on the order of one in a hundred thousand or rarer.
The inaction side is where the cohorts in the question matter. A US healthcare-worker serosurvey found 4% seronegative and 2% equivocal for measles IgG — a roughly 6% immunity gap — and a 2025 meta-analysis of 23,236 vaccinated people pooled seropositivity at 87.8%, falling to 84.3% among single-dose recipients. The 1963-67 killed-vaccine cohort is a separate, smaller group that ACIP explicitly tells to revaccinate, because the inactivated product conferred little durable protection. The catch is that an immunity gap is not the same as realized regret: with 2,288 confirmed US cases in 2025 against a population of roughly 340 million, the national attack rate stayed near 0.0007%, so most seronegative adults were never exposed at all. What gives the gap its weight is the severity tail — 11% of 2025 cases were hospitalized and there were deaths — so the rare intersection of “no immunity” and “exposed” is consequential. The honest reading: skipping leaves a measurable hole in protection for a minority of these cohorts, getting the dose closes it at trivial cost, and the realized-regret asymmetry favors acting even though almost no one in either group will ever face the outcome that would make the choice matter.
Sumber: tindakan
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
1/2 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
[1]Journal of Allergy and Clinical Immunology / NCBI PMC — Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990–2016
Terverifikasi
Telaah sejawat
MMR-containing vaccine anaphylaxis reporting rate of 0.6 per 1 million doses distributed (overall vaccine rate 1.3 per million).
Kutipan
“The estimated rate of anaphylaxis reported to VAERS during 1990 to 2016 after MMR was 0.6 per 1 million doses distributed.”
Data sumber dari
2019-01-01
Diakses
2026-06-13
Verifikasi
Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
Perhitungan
Anaphylaxis is the canonical serious adverse event of MMR. 0.6 per 1,000,000 doses = 6e-7. The action regret_rate is set conservatively above that floor (1e-5) to absorb other rare serious events (febrile seizure, transient thrombocytopenia) the VIS lists. The dominant 'downside' of acting for an already-immune adult is a redundant dose, which yields peace of mind rather than regret, so it is not counted as regret. This is the matched-severity proxy: action's regret-worthy outcome is a serious AE, not 'the shot turned out unnecessary'.
[2]U.S. Centers for Disease Control and Prevention — MMR Vaccine Information Statement (VIS)
Laporan pemerintah
Serious adverse events from MMR are characterized as a very remote chance; common effects are minor (sore arm, fever, mild rash).
Kutipan
“As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.”
Data sumber dari
2025-01-31
Diakses
2026-06-13
Perhitungan
Qualitative confirmation that the action side's serious downside is 'very remote.' Establishes that the regret-worthy outcome of acting is rare and severe (an AE), distinct from the common, non-regret outcome of a redundant-but-protective dose. No numeric rate on this page; the numeric anchor is PMC6580415.
Sumber: tidak bertindak
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
3/6 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
[1]Infection Control and Hospital Epidemiology (PubMed) — Measles immunity in a population of healthcare workers
Terverifikasi
Telaah sejawat
Among 2,473 US healthcare workers tested for anti-measles IgG, 4% were seronegative and 2% equivocal — a ~6% immunity gap.
Kutipan
“Ninety-three workers (4%) were seronegative, and 56 (2%) were equivocal.”
Data sumber dari
1994-01-01
Diakses
2026-06-13
Verifikasi
Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
Perhitungan
Population-matched anchor: US healthcare workers, one of the named higher-risk cohorts. Seronegative (4%) + equivocal (2%) = 6% lacking a measles immunity marker → inaction proxy 0.06. This is an immunity-gap upper bound, not a realized-regret rate: most seronegative people are never exposed (2025 national attack rate ~ 2,288 / ~340M ~ 0.0007%). The proxy measures who is even eligible for potential regret if exposed.
[2]eClinicalMedicine (The Lancet Discovery Science) — Measles seropositivity in previously vaccinated individuals: a systematic review and meta-analysis
Telaah sejawat
Pooled seropositivity among vaccinated individuals was 87.8% (so ~12.2% seronegative); single-dose recipients 84.3% seropositive (~15.7% seronegative), across 23,236 individuals from 10 countries.
Kutipan
“Pooled seropositivity was 87·8% (95% CI, 83·9%–91·2%) across 23,236 vaccinated individuals”
Data sumber dari
2025-01-01
Diakses
2026-06-13
Perhitungan
Current (2025) pooled anchor confirming waning: ~12% of vaccinated adults are below seropositivity thresholds, rising to ~16% for single-dose recipients. Verified verbatim via Playwright (Lancet 403s WebFetch). Used to frame the spread; the 6% HCW figure is kept as the population-matched headline rather than the 12-16% pooled (mixed-country, assay-threshold) number to avoid overstating realized susceptibility.
[3]U.S. Centers for Disease Control and Prevention — Measles Vaccination for Specific Groups
Laporan pemerintah
ACIP recommends revaccinating recipients of killed/inactivated or unknown-type measles vaccine from 1963-1967; healthcare personnel without presumptive immunity need 2 doses.
Kutipan
“The ACIP recommends re-vaccinating anyone who received measles vaccine of unknown type, inactivated measles vaccine, or further attenuated measles vaccine accompanied by immunoglobulin or high-titer measles immune globulin (no longer available in the United States) during these years with 1 or 2 doses.”
Data sumber dari
2024-07-15
Diakses
2026-06-13
Perhitungan
Establishes that the 1963-67 killed-vaccine cohort is functionally unprotected per ACIP and explicitly advised to revaccinate — the qualitative basis for why skipping carries downside for this cohort. This cohort is <5% of adults and overlaps the pre-1957 presumed-immune group, so it informs but does not set the numeric anchor.
[4]CDC MMWR / NCBI PMC — Measles Update — United States, January 1–April 17, 2025
Terverifikasi
Laporan pemerintah
Of 800 confirmed 2025 cases through April 17, 96% were unvaccinated or unknown status, 11% hospitalized, 3 deaths.
Kutipan
“Overall, 771 (96%) patients have been unvaccinated or had unknown vaccination status”
Data sumber dari
2025-04-24
Diakses
2026-06-13
Verifikasi
Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
Perhitungan
Establishes the severity tail that makes the immunity gap consequential: 11% of measles cases hospitalized, 3 deaths in the period, 96% of cases in the unvaccinated/unknown. The realized harm to someone in the immunity gap who is exposed is severe; this is what gives the inaction proxy its weight.
[5]U.S. Centers for Disease Control and Prevention — Measles Cases and Outbreaks — 2025 Data Summary
Terverifikasi
Laporan pemerintah
Full-year 2025: 2,288 confirmed US measles cases — the largest annual count since 1992.
Kutipan
“For the full year of 2025, a total of 2,288 confirmed* measles cases were reported in the United States.”
Data sumber dari
2026-06-12
Diakses
2026-06-13
Verifikasi
Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
Perhitungan
Sets the exposure backdrop: 2,288 cases / ~340M US population ~ 0.0007% national attack rate. This is why the 6% immunity-gap proxy is explicitly an upper bound on potential regret, not realized regret — exposure remained geographically concentrated and rare nationally even in the worst year since 1992.
[6]The Texas Tribune — Texas measles victim's parents stand by decision to not vaccinate
Artikel berita
After their unvaccinated 6-year-old daughter died of measles in Gaines County, Texas in February 2025, the parents said in a recorded statement that the death did not change their opposition to the MMR vaccine.
Kutipan
“"We would absolutely not take the MMR," the mother said, adding that her stance on vaccination has not changed after her daughter's death.”
Data sumber dari
2025-03-20
Diakses
2026-07-03
Perhitungan
Illustrative real-world counterpoint, not a numeric input to the 0.06 inaction proxy: a parent's decision about a child's routine MMR dose amid a measles death is a different population and decision from the adult titer/booster question this entry covers, and one family's account is not a survey. Cited to support the body-text point that documented post-outbreak reactions do not uniformly run toward regretting non-vaccination.
Catatan
proxy_only: there is no direct "regret getting/skipping an MMR booster" survey; both rates are stand-ins. The inaction rate (6%) is the share of a US healthcare-worker serosurvey lacking an immunity marker (seronegative + equivocal), i.e. an upper bound on who is even eligible for regret, NOT a measured regret rate — most seronegative people are never exposed (2025 national attack rate ~0.0007%). The susceptibility spread is wide and assay-dependent: 6% (US HCW IgG), 12.2% (2025 pooled meta-analysis), up to ~37.6% in one Olmsted County, MN commercial-assay study whose high figure is largely a below-titer-threshold artifact (titer below cutoff does not equal susceptible, because anamnestic memory-B-cell immunity is not captured) and is therefore excluded from the anchor. The 1963-67 killed-vaccine cohort is <5% of adults and overlaps the pre-1957 presumed-immune group, so it is a qualitative ACIP-revaccinate flag rather than the numeric anchor. The action anaphylaxis figure (0.6/million) is a passive-surveillance VAERS reporting rate, not a measured incidence. The meta-analysis pools 10 countries, not US-only. CDC publishes immunity and case data, not regret; this entry should not be read as advice to get or skip a dose.
